Development and immunogenicity of recombinant GapA+ Mycoplasma gallisepticum vaccine strain ts-11 expressing infectious bronchitis virus-S1 glycoprotein and chicken interleukin-6

• DOI: 10.1016/j.vaccine.2011.02.035
• Publication Date: 2011-02-26T12:26:32Z
• Authors: Pollob K. Shil; Anna Kanci; Glenn F. Browning; Philip F. Markham
• Keywords: 2. Zero hunger; Vaccines, Synthetic; 0303 health sciences; Membrane Glycoproteins; Interleukin-6; Blotting, Western; Body Weight; Mycoplasma gallisepticum; Viral Vaccines; Antibodies, Viral; Vaccines, Attenuated; Antibodies, Bacterial; 3. Good health; 03 medical and health sciences; Viral Envelope Proteins; Agglutination Tests; Bacterial Vaccines; Spike Glycoprotein, Coronavirus; Animals; Adhesins, Bacterial; Coronavirus Infections; Chickens; Poultry Diseases

Mycoplasma gallisepticum (MG) is a major pathogen of poultry that causes chronic respiratory disease in chickens and infectious sinusitis in turkeys. A live attenuated vaccine, ts-11, has been used for the control of MG in several countries. The efficacy of this vaccine is highly dose dependent and the flock antibody response is weak. To improve the functionality of the vaccine and investigate its potential as a delivery vector for foreign antigens and immunomodulatory proteins, we developed a derivative of ts-11 expressing infectious bronchitis virus-S1 glycoprotein (IBV-S1) and releasing chicken interleukin-6 into the extracellular milieu (MG ts-11 C3 (+CS)) using a transposon-based delivery vector. Following administration of MG ts-11 C3 (+CS) to chickens by eye-drop, an antibody response to MG and IBV-S1, as determined by the rapid serum agglutination test (RSA) and Western blotting, respectively, could be detected. Birds inoculated with the recombinant vaccine had significantly enhanced weight gain and were partially protected against damage by pathogenic IBV. These results indicate that the ChIL-6 released by MG ts-11 C3 (+CS) may have had a non-specific effect on growth rate. They also suggest that ts-11 is a promising vaccine vector, capable of delivering heterologous protective antigens, and may also provide non-specific benefits when engineered to express immunomodulatory proteins. With some improvements in the expression system, it could be used to induce a targeted immune response against specific mucosal pathogens, and co-expression of several antigens would allow development of a novel multivalent vaccine.